Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Avera McKennan

Neither a doctor nor a teaching hospital

Research payments

$307,609

33 payments

Through program year 2025, Avera McKennan is reported as receiving $307,609 in research payments, across 33 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $138,840 20
2024 Research $4,595 1
2023 Research $57,864 2
2021 Research $101,238 6
2019 Research $5,072 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $142,411 12 payments
  2. Novartis Pharmaceuticals Corporation $57,864 2 payments
  3. Cumberland Pharmaceuticals, Inc. $35,667 8 payments
  4. Genmab U.S., Inc. $35,000 1 payment
  5. Daiichi Sankyo Inc. $31,595 6 payments
  6. Janssen Research & Development, LLC $5,072 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Co $74,238 1 payment
  2. A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab M $68,172 11 payments
  3. Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (Ipf) $35,667 8 payments
  4. A Phase III Randomized Study to Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer $35,524 1 payment
  5. A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer $35,000 1 payment
  6. Ds1062-A-U301 $31,595 6 payments
  7. A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected Tki in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase $22,340 1 payment
  8. A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant $5,072 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record